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A Delphi process to address medication
appropriateness for older persons with
multiple chronic conditions
Terri R. Fried1,2*, Kristina Niehoff1, Jennifer Tjia3, Nancy Redeker4 and Mary K. Goldstein5,6
Abstract
Background: Frameworks exist to evaluate the appropriateness of medication regimens for older patients with
multiple medical conditions (MCCs). Less is known about how to translate the concepts of the frameworks into
specific strategies to identify and remediate inappropriate regimens.
Methods: Modified Delphi method involving iterative rounds of input from panel members. Panelists (n = 9) represented
the disciplines of nursing, medicine and pharmacy. Included among the physicians were two geriatricians, one general
internist, one family practitioner, one cardiologist and two nephrologists. They participated in 3 rounds of web-based
anonymous surveys.
Results: The panel reached consensus on a set of markers to identify problems with medication regimens, including
patient/caregiver report of non-adherence, medication complexity, cognitive impairment, medications identified by
expert opinion as inappropriate for older persons, excessively tight blood sugar and blood pressure control among
persons with diabetes mellitus, patient/caregiver report of adverse medication effects or medications not achieving
desired outcomes, and total number of medications. The panel also reached consensus on approaches to address these
problems, including endorsement of strategies to discontinue medications with known benefit if necessary because of
problems with feasibility or lack of alignment with patient goals.
Conclusions: The results of the Delphi process provide the basis for an algorithm to improve medication regimens
among older persons with MCCs. The algorithm will require assessment not only of medications and diagnoses but also
cognition and social support, and it will support discontinuation of medications both when risks outweigh benefits and
when regimens are not feasible or do not align with goals.
Keywords: Medications, Chronic conditions, Polypharmacy
Background
A growing body of evidence describes a number of prob-
lems with current patterns of prescribing for older per-
sons with multiple chronic conditions (MCCs). These
patients are underrepresented in randomized controlled
trials providing the data underlying many disease man-
agement guidelines, and they may derive less benefit
from and be at increased risk of harm from guideline-
supported medications as compared to younger persons
and those with lower chronic disease burden [1–3].
Older persons with MCCs take multiple medications
and have complicated medication regimens, which
increases the risk of drug-drug and drug-disease interac-
tions [4] and can result in decreased medication adher-
ence [5, 6]. Polypharmacy, variably defined according to
the number of prescribed medications, has been associ-
ated in a large number of observational studies with an
increased risk of a range of adverse events [7]. While it
remains unclear whether this risk is due to the number
of medications per se, there is preliminary evidence that
medication deprescribing can improve outcomes [8, 9].
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Current guidance for improving medication prescrib-
ing for older persons consists of either narrowly focused
explicit medication review or broadly described implicit
review based on general principles. Explicit criteria, such
as the AGS Beers [10] and STOPP [11] criteria, provide
specific recommendations for avoiding medications
based on increased risks of adverse reactions in older
persons and drug-drug/drug-disease interactions. The
Medication Appropriateness Index (MAI) [12] provides
additional criteria for implicit medication review, includ-
ing indication, effectiveness, instructions, duplication
and cost. Recognizing that additional factors affect the
appropriateness of medication prescribing for the com-
plex older patient, a number of investigators have ex-
panded the basis for implicit medication review by
proposing conceptual frameworks to evaluate appropriate-
ness [3, 13–15] and to deprescribe medications [16, 17].
These frameworks include the concepts of evaluating
time-to-benefit, patients’ preferences and goals and indi-
vidually tailored benefits and harms or burdens. These
frameworks provide a general description of the concepts
without more specific strategies for applying these con-
cepts to individual patients and regimens.
Similarly, interventions to improve medication regimens
have either utilized explicit review to focus on a single
medication/medication class or have utilized implicit re-
view, requiring evaluations performed by pharmacists, phy-
sicians, and/or multidisciplinary teams.[18–20] The former
type of intervention is easier to implement but is narrow in
focus. The latter form of intervention, while comprehen-
sive, is resource intensive and it is not known how individ-
ual practitioners apply the more general principles of
appropriateness. Moving from general concepts or princi-
ples to more explicit strategies for identifying inappropriate
medication regimens and deprescribing medications would
help to fill this gap and serve as the basis for interventions
that are both comprehensive and feasible. The purpose of
this study was to develop a set of strategies or approaches
for identifying and addressing problems with medication
regimens for older adults with MCCs, focusing on the issue
of deprescribing to reduce medication burden. In the ab-
sence of a strong evidence base, a Delphi panel was con-
vened to obtain expert consensus.
Methods
Participants
Participants for the Delphi panel were selected to repre-
sent a broad range of expertise and perspectives as related
to the care of the older person with MCCs. The nine pan-
elists represented the disciplines of nursing, medicine and
pharmacy. Physicians from a number of specialties were
selected in order to ensure that any differences in perspec-
tives among these specialties would be represented.
Among the physicians, there were two geriatricians, one
general internist, one family practitioner, one cardiologist
and two nephrologists. Panelists were selected based on
their record of scholarship regarding the management of
older persons with MCCs and/or endorsement by a pro-
fessional society as having expertise in this area. The first,
second and last authors organized the work of the panel
as part of the core research team but did not participate
as members. The Human Subjects Committee of Yale
University determined that the study qualified for exemp-
tion. Participants received an information sheet describing
the study with assent indicated by completion of the
Delphi survey.
Study design
The panel used a modified Delphi technique [21, 22] to
develop strategies for identifying problems with medica-
tion regimens for patients with MCCs and making
changes in the regimens. The Delphi technique consists
of iterative rounds of input from panel members, work-
ing anonymously, in which they are provided feedback
from earlier rounds. The process included two modifica-
tions to the standard Delphi technique. The first was
that the process began with a “time zero” panel meeting
conducted by telephone. Although not generally used in
the Delphi process, the time zero meeting has been used
in the closely related RAND/UCLA appropriateness
method [23]. One purpose of the meeting was to clarify
the task to be addressed in the Delphi process, because
of the complexity of the topic and the controversies re-
garding aging and its relationship to undertreatment ver-
sus overtreatment. The other purpose was to generate
approaches to the identification and remediation of
problems with medications among persons with MCCs.
The second modification to the Delphi technique was
that, rather than having the panel generate specific
items, the core research team generated a candidate set
of items for the panel to consider based on the results of
the time zero meeting and literature review.
In preliminary work, the core team conducted two sys-
tematic reviews. The first of these reviews addressed the
question of how the presence of comorbidity altered the
benefits and harms of treatment for an index condition
[24] and the second addressed the question of the adverse
clinical outcomes associated with polypharmacy [7].
Prior to the time zero meeting, the panel received a
document containing: 1) a statement of the problem; 2)
the objectives for the Delphi process; 3) a summary of
the systematic reviews; and 4) questions for the meeting.
The panel was asked to consider three questions: 1) how
do we know if there is a potential problem with a
patient’s medication regimen? 2) how do we know if a
regimen is consistent with a patient’s treatment goals? 3)
what are approaches for reducing medications if there is
agreement that the patient is taking too many?
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Following the time zero meeting, the core team devel-
oped preliminary sets of items representing different
strategies. These items were presented to panelists for
their feedback through a website, with panelists provid-
ing their feedback anonymously. In the first round of the
Delphi process, participants were asked to undertake
one of two tasks for each of the items. For items that
stated a fact, they were asked to rate their level of agree-
ment with each item on a 5-point Likert scale: “Strongly
Agree, Agree, Neutral, Disagree, Strongly Disagree,” and
to provide comments to support their rating. For items
seeking to establish a threshold for decision making,
such as the level of hemoglobin A1C (HgbA1c) repre-
senting excessively tight control, they were asked to
provide a number and to provide comments to support
this number. Participants were invited to suggest
changes to the language of the items and to provide
additional items.
After the first round, responses were compiled to
evaluate the level of consensus. Consensus was consid-
ered to be achieved for statements of fact if: a) all partic-
ipants provided a rating of “agree” or “strongly agree;”
and b) no participant recommended a change in word-
ing. Consensus was considered to be achieved for
threshold statements if all participants provided the
same number. In the second round of the Delphi
process, participants were presented with statements for
which consensus was not achieved. Participants were
also provided with their own and other panelists’ rat-
ings/numbers and comments for these statements. They
were given the task of re-rating/re-assigning a number
based on the consideration of their own and others’
prior responses, as well as rating new items that were
proposed during the prior round. The same procedure
was followed for the third and final round. In each of




In addition to providing content for the specific items
described below, the discussion highlighted the limited
data available to assess the risks and benefits of medica-
tion regimens and fit with patients’ goals. Panel members
pointed out that there may be under-recognized effects
of medications on outcomes that are important to pa-
tients, such as the beneficial effect of statins on walking
performance and symptoms of claudication in patients
with peripheral vascular disease [25, 26]. The panel also
highlighted the problems of the exclusion of older per-
sons with MCCs from clinical trials and the inappropri-
ateness of extrapolating data from younger and healthier
populations. The panel considered the fact that time to
benefit is a very useful concept for improving decision
making around cancer screening and diabetes manage-
ment, but discussed the lack of evidence regarding the
time to benefit for commonly used medications, such as
antihypertensives and statins, for other chronic condi-
tions. Finally, the panel felt that there was insufficient
data to create strategies to tailor medication regimens to
patients’ treatment goals. While they acknowledged that
having patients prioritize their goals in terms of what
was most important to them, they also discussed that it
was unclear how to prescribe to best meet those goals.
Development of the overall approach for identifying and
addressing problems with medication regimens
The core team identified two steps necessary to organize
the work of the Delphi panel: 1) development of strat-
egies for identifying patients who have a problematic
medication regimen, and 2) development of strategies
for addressing the problem(s) with the regimen. The first
step required developing both a potential taxonomy of
problems with medication regimens and corresponding
markers or indicators for each of these problems, since
consensus could not be reached about how to identify a
patient with a problem if there was not consensus about
what the problems were. In order to avoid expanding
the work of the Delphi panel beyond 3 rounds of ratings,
the panel was asked to consider the taxonomy and cor-
responding markers simultaneously rather than sequen-
tially. If consensus could not be reached on an element
of the taxonomy, then the ratings regarding the markers
were not further analyzed. Regarding the second step,
the team recognized that the lack of available data would
make it challenging to reach consensus regarding spe-
cific strategies for addressing problems, and therefore
simultaneously developed a set of general strategies in
addition to more specific ones (Fig. 1).
Delphi process: strategies for identifying problematic
medication regimens
The Delphi panel reached consensus on a taxonomy of
problems with medication regimens, including regimens
that are not feasible for the patient to manage, regimens
that contain medications with no benefit, regimens that
place the patient at more than minimal risk of suffering
an unintended adverse event, and regimens that are not
consistent with patient goals. Details of the markers to
identify each of these problems are provided in Fig. 2.
While the panel agreed in Round 1 that polypharmacy
was a marker for elevated risk, they did not reach con-
sensus on the number of medications that constituted
polypharmacy. In Round 1, the range of responses was
from four or more medications to ten or more. In
Round 2, the range narrowed from five or more to seven
or more, but did not narrow any further in the final
round. The panelists also agreed that excessively tight
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control of blood sugars and blood pressure in DM was a
marker for increased risk, but the range of thresholds
was similarly broad in Round 1. These ranges tightened
considerably, so that consensus was either reached or al-
most reached by Round 3. Figure 2 includes items for
which consensus for thresholds for HgbA1C and blood
pressure was not fully achieved, but for which there was
only one differing response that was in close range to
the majority response.
Delphi process: strategies to address medication problems
The general and specific strategies for which the panel
reached consensus are presented in Table 1. In addition to
discontinuation of medications with increased risk of
harm, these strategies include the discontinuation of med-
ications providing benefit depending upon the patient’s
valuations of benefits and harms and the ability of the pa-
tient to manage the regimen. Consensus was not reached
for several proposed strategies. These included the discon-
tinuation of a number of vitamins and supplements that
were identified by some Delphi panel members as having
no evidence of benefit, such as multivitamins, gingko
biloba and vitamin C. As described in the Time Zero
meeting, the panel did not believe that there was sufficient
evidence to create specific strategies based on the elicit-
ation of patients’ treatment goals. During the panel
process, there were concerns about the ability to convey
risk information in a manner that the majority of patients
would have an accurate understanding, and therefore
could not reach agreement about strategies for discon-
tinuing preventative medications based on patients’ valua-
tions of the risk reduction they provide. In addition, while
the panel agreed that there were risks associated with
polypharmacy, there was no consensus achieved regarding
the discontinuation of medications based on an evaluation
of the cumulative risks and benefits of a regimen consid-
ered as a whole.
Discussion
In the absence of a strong evidence base to guide the
optimization of medication regimens for older persons
with MCCs, a Delphi panel was convened to develop
strategies for recognizing and addressing problems with
medication regimens among this patient population. Be-
fore beginning the process of building consensus, the
panel, participating in a time zero meeting, identified the
lack of data as a major barrier to the work of the panel.
Specifically, they pointed to the potential for under-
recognized and under-studied benefits of medications on
outcomes of importance to patients as well as the poten-
tial for harm and to the absence of data regarding time
to benefit for many commonly used medications. They
also identified a lack of data on how to tailor medication
regimens to be consistent with patients’ goals. Nonethe-
less, the panel reached consensus on identifying a
detailed specification of problems with medication regi-
mens with markers delineating the clinical circum-
stances under which these occur. The work of the panel
provides initial steps necessary for moving from general
principles and concepts outlined in frameworks address-
ing the appropriateness of medications among older
persons [3, 13–15] to an algorithm for medication re-
view. The panel frequently had more difficulty reaching
consensus about specific strategies for addressing these
Fig. 1 Clinical strategies to improve medication regimens among older persons and corresponding tasks for Delphi panel
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*One panelist provided HgbA1c< 7.5
**One panelist provided SBP < 140
Regimens that include medications 
lacking benefit
Medications for which there are no indication, including 
medications started at an earlier time for self-limited
problems 
Regimens that are not feasible 
for the patient to manage
Patient and/or caregiver self-report of non-adherence
Patient and/or caregiver self-report of problems with cost
Medication complexity, number of medications, number of 
doses, frequency of administration
Evidence of failure to refill medication, as obtained from 
electronic medical record, pharmacist, or other available 
sources
Patient cognitive impairment with lack of compensatory 
social support
Regimens that place the patient 
at more than minimal risk of 
suffering an unintended 
medication adverse effect
Medications identified by expert opinion as being 
inappropriate for older persons, such as those included in 
the Beers and STOPP lists
Polypharmacy (see text for discussion of number of 
medications defining polypharmacy)
Excessively tight control of DM (HgbA1c < 7.5) among older 
persons with 2 or more comorbid conditions
Excessively tight control of DM (HgbA1c < 8)* among older 
persons with functional disability 
Excessively tight control of DM (HgbA1c < 8) among older 
persons with life expectancy < 5 years
Excessively tight control of HTN (SBP< 130, DBP < 80)**in 
patients with DM
Treatment of HTN that results in orthostatic hypotension 
Regimens that are not consistent 
with the patient’s goals of 
treatment, when the patient is 
able to articulate these goals
Patient self-report of a significant or serious adverse effect 
of a medication
Patient self-report that the medication regiment is not 
achieving the desired outcome
Benefits associated with medications prescribed for 
prevention, expressed in terms of absolute risk reductions, 
not sufficiently large from the patient’s perspective 
Problem Marker(s) of problem 
Fig. 2 Problems with medications and their corresponding markers
Fried et al. BMC Geriatrics  (2016) 16:67 Page 5 of 8
problems. Their endorsement of general strategies repre-
sents an important confirmation of principles that have
been presented in the frameworks but have not yet been
widely adopted in clinical practice. These include con-
sensus about the need to consider discontinuation of
medications even when they have known benefits,
because of the presence of countervailing harms or bur-
dens. The difficulties experienced by the panel in creat-
ing consensus-based detailed strategies for how to
balance these considerations, particularly in the context
of patients’ values, highlights the complexities of medi-
cation prescribing for older persons with MCCs.
The work of the panel made more strides in identify-
ing strategies for how to identify a problematic medica-
tion regimen than for how to address those problems.
Currently used criteria endorsed by the panel, including
the MAI [12], STOPP [11], and AGS Beers [10] focus on
the medication appropriateness as defined by the medi-
cations themselves and the patient’s medical diagnosis.
The panel added criteria for identification of overtreat-
ment of diabetes mellitus and of hypertension among
persons with diabetes. This is in general agreement with
a number of disease management guidelines [27–29].
The panel also further expanded the definition of appropri-
ateness by endorsing additional strategies that evaluate the
medication regimen according to patient factors reaching
beyond the physiologic effects of the regimen. One dimen-
sion of this evaluation is an assessment of the feasibility of
the regimen. Beyond the issue of cost, the panel identified
the need to evaluate the complexity of the regimen, par-
ticularly in the context of the patient’s cognitive abilities
and social support. By supporting an evaluation of the regi-
men in the context of the patient’s ability to adhere, the
panel endorsed the notion that appropriateness is not de-
termined solely by the effects of the medication. Following
from this expanded notion of appropriateness, the panel
endorsed a strategy of simplifying the regimen for patients
who cannot compensate for the complexity of their
regimens, even if this means discontinuing medications
with clear benefits. Such an approach is a departure
from the standard notion that medical appropriateness
dictates the regimen, and interventions are aimed at
the goal of having the patient adhere to that regimen
[30]. The panel’s recommendations explicitly recognize
the potential for irreconcilable conflicts between what
may be medically indicated and what the older patient
with cognitive impairment and limited support can
reasonably manage, the only solution to which is to
adjust the regimen.
A second dimension of the evaluation of appropriate-
ness in the context of patient-related factors endorsed by
the panel is the consideration of patients’ goals. This is not
a new concept, as it has been included in a number of
conceptual frameworks and/or guiding principles for man-
aging medications among older persons [3, 13–15]. How-
ever, despite the widespread recognition of the need to
tailor medications to patients’ preferences and goals, the
panel was unable to come to agreement about specific ap-
proaches to do this beyond discontinuing medications with
unacceptable adverse effects. The panel’s failure to develop
additional specific strategies reflects the complexities of
prescribing medications according to patients’ goals. First,
there is little evidence of the effect of standard medical
therapies on outcomes other than survival. While many
older persons prioritize preservation of function over life
prolongation [31], there are few data informing care plan-
ning to achieve this outcome. Second, while clinical experi-
ence may be able to guide clinicians whose patients desire
a purely palliative approach to their care, this is not likely
to be a common goal except for patients at the very end of
life. In the absence of issues with feasibility, the burdens of
medications may not be viewed as excessive, even by
patients who are prescribed multiple medications. One
study of patients’ views on the burden and benefits of med-
ications suggests, not surprisingly, that the majority of
older persons want a balance between the two and are will-
ing to put up with multiple medications and some adverse
effects for future benefits [32]. The ability to translate
this desire for balance into a specific treatment plan
Table 1 Strategies for addressing problems with medication
regimens
General approaches
• For the patient who is non-adherent because of issues of feasibility, it
is advisable to reduce the total burden of medication in addition to
providing increased support for taking medications, even including
medications with known benefit.
• It is reasonable to undertake dose reduction or discontinuation of
medications associated with both benefits and side effects if the
patient views the side effects as more important than the benefits.
• It is reasonable to discontinue medications prescribed for primary/
secondary disease prevention if the patient views the reduction of risk
as insufficiently large.
• Clinicians and patients should have a discussion to prioritize patients’
goals for their medications and decide on a regimen that reflects this
priority.
• Patients with polypharmacy even after steps are taken to discontinue
medications should be informed of the risks associated with polypharmacy.
Specific approaches
• Medications on the Beers and STOPP lists should be considered for
discontinuation, unless there is a compelling reason not to do so.
• Medications without an indication should be discontinued.
• A trial of dose reduction/discontinuation of medications with patient
self-report of adverse effect should be undertaken, with re-evaluation
to assess for improvement and possible rechallenge.
• Dose reduction/discontinuation of medications should be undertaken
in patients with excessively tight control of DM.
• Dose reduction/discontinuation of medications should be undertaken
in patients with excessively tight control of HTN.
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is a multifaceted and complicated task the panel was
unable to tackle.
The study has several limitations. While the Delphi
panel consisted of clinicians representing a range of
disciplines, it would have been even more compre-
hensive with the inclusion of additional subspecialties,
such as endocrinology and rheumatology. Not all of
the panelists provided ratings for all rounds, but each
panelist participated in at least one round of ratings.
With its focus on problems associated with polyphar-
macy and deprescribing, the Delphi process did not
address the issue of failures to prescribe recom-
mended medications, which is also highly prevalent
among older persons [33].
Conclusions
The results of the Delphi process used in this study pro-
vide specific strategies for identifying problems with
medications, including recognition when medication
regimens are not feasible, are associated with an excess
risk of harm, and when they are not meeting the pa-
tient’s goals. Building on the work of individual investi-
gators who have proposed frameworks for addressing
medications among older persons, the strategies devel-
oped by the panel represent consensus opinion sup-
ported by a broad range of expertise. The strategies
identified by the panel provide the first steps in imple-
menting a clinical algorithm, based on a combination of
explicit and implicit review, to address polypharmacy.
The work of the panel suggests that this algorithm will
require a comprehensive assessment of the patient’s
medication regimen and health status; adherence with
medications; patients’ reports of problems with medica-
tions and goals; and evaluation of the patient’s cognitive
status and available social support. Additional work will
be required to determine the best tools to use for this
assessment. Based on this assessment, deprescribing can
be done with varying levels of complexity and clinical
judgment. The most straightforward involves discontinu-
ation of medications without indications, those included
in consensus-derived lists of potentially inappropriate
medications, those leading to potential overtreatment of
DM and HTN, and those for which adverse effects out-
weigh benefits. Many patients may still be left with a
medication regimen that is not feasible and/or continues
to confer the risks associated with polypharmacy. The
fact that the panel struggled to reach consensus and find
specific strategies for these patients suggests that further
deprescribing will require complex clinical judgment in
the context of what matters most to the patient.
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